Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: TAK-279

First Posted Date: 2024-08-12

Last Posted Date: 2024-12-27

Lead Sponsor: Takeda

Target Recruit Count: 1300

Registration Number: NCT06550076

Locations: 🇺🇸
Total Dermatology, Birmingham, Alabama, United States
🇺🇸
University of Alabama Hospital - Whitaker Clinic -, Birmingham, Alabama, United States
🇺🇸
Cahaba Dermatology Skin Health Center, Hoover, Alabama, United States

and more 277 locations

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

Not yet recruiting

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions: Other: No Intervention

First Posted Date: 2024-08-05

Last Posted Date: 2024-11-14

Lead Sponsor: Takeda

Target Recruit Count: 30

Registration Number: NCT06538064

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

Recruiting

Conditions: Alpha1-Antitrypsin Deficiency

Interventions: Other: No Intervention

First Posted Date: 2024-07-22

Last Posted Date: 2024-10-01

Lead Sponsor: Takeda

Target Recruit Count: 1000

Registration Number: NCT06512454

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇩🇪
Universitätsklinikum Aachen AöR, Aachen, North Rhine-Westphalia, Germany

A Study of TAK-861in People With Narcolepsy Type 1

Phase 3

Recruiting

Conditions: Narcolepsy Type 1

Interventions: Drug: TAK-861
Drug: Placebo

First Posted Date: 2024-07-17

Last Posted Date: 2024-12-03

Lead Sponsor: Takeda

Target Recruit Count: 93

Registration Number: NCT06505031

Locations: 🇦🇺
Takeda Site 1, Glebe, New South Wales, Australia
🇧🇪
Takeda Site 2, Alken, Belgium
🇧🇪
Takeda Site 3, Erpent, Belgium

and more 10 locations

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

Phase 3

Recruiting

Conditions: Narcolepsy Type 1

Interventions: Drug: TAK-861
Drug: Placebo

First Posted Date: 2024-06-24

Last Posted Date: 2024-12-11

Lead Sponsor: Takeda

Target Recruit Count: 152

Registration Number: NCT06470828

Locations: 🇺🇸
Takeda Site 4, Orlando, Florida, United States
🇺🇸
Takeda Site 42, Cleveland, Ohio, United States
🇺🇸
Takeda Site 39, Redwood City, California, United States

and more 39 locations

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Recruiting

Conditions: Acquired Hemophilia A

Interventions: Drug: Susoctocog Alfa (Genetical Recombination)

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: Takeda

Target Recruit Count: 25

Registration Number: NCT06461533

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Phase 3

Not yet recruiting

Conditions: Pouchitis

Interventions: Drug: Vedolizumab
Drug: Concomitant Antibiotic Therapy

First Posted Date: 2024-06-05

Last Posted Date: 2024-06-05

Lead Sponsor: Takeda

Target Recruit Count: 30

Registration Number: NCT06443502

Locations: 🇧🇪
UZ Leuven, Leuven, Vlaams Brabant, Belgium
🇭🇷
Klinika Za Djecje Bolesti Zagreb, Zagreb, Grad Zagreb, Croatia
🇮🇱
Schneider Childrens Medical Center of Israel Petah Tikvah PIN, Petach Tikvah, Israel

and more 13 locations

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)

Interventions: Drug: Recombinant ADAMTS13

First Posted Date: 2024-06-04

Last Posted Date: 2024-07-03

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT06441578

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Phase 3

Not yet recruiting

Conditions: Cytomegalovirus (CMV)

Interventions: Drug: Maribavir

First Posted Date: 2024-06-03

Last Posted Date: 2024-06-06

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06439342

Locations: 🇨🇳
Peking University People's Hospital, Beijing, North China, China

A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)

Completed

Conditions: Von Willebrand Disease (VWD)

Interventions: Other: No Intervention

First Posted Date: 2024-05-30

Last Posted Date: 2024-11-11

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT06433778

Locations: 🇬🇧
Leeds Teaching Hospital, Leeds, United Kingdom
🇬🇧
Manchester University, Manchester, United Kingdom
🇬🇧
Imperial College Healthcare, London, United Kingdom

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy